Published in Oncotarget on August 21, 2015
Survival kinase genes present prognostic significance in glioblastoma. Oncotarget (2016) 0.79
Genomic and transcriptomic characterization of skull base chordoma. Oncotarget (2016) 0.77
Dendrosomal nanocurcumin and p53 overexpression synergistically trigger apoptosis in glioblastoma cells. Iran J Basic Med Sci (2016) 0.75
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature (2008) 75.40
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
An integrated genomic analysis of human glioblastoma multiforme. Science (2008) 51.36
The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol (2007) 49.11
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
Identification of human brain tumour initiating cells. Nature (2004) 38.87
In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (2004) 24.42
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell (2006) 21.66
Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev (2007) 17.20
ONCOMINE: a cancer microarray database and integrated data-mining platform. Neoplasia (2004) 17.08
Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell (2006) 15.16
Wnt signaling: a common theme in animal development. Genes Dev (1997) 12.94
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci U S A (2003) 10.56
Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. Cancer Cell (2012) 6.71
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science (2014) 6.09
An oncogenomics-based in vivo RNAi screen identifies tumor suppressors in liver cancer. Cell (2008) 5.47
The TAK1-NLK-MAPK-related pathway antagonizes signalling between beta-catenin and transcription factor TCF. Nature (1999) 4.01
WNT/TCF signaling through LEF1 and HOXB9 mediates lung adenocarcinoma metastasis. Cell (2009) 3.76
FoxM1 promotes β-catenin nuclear localization and controls Wnt target-gene expression and glioma tumorigenesis. Cancer Cell (2011) 3.58
Rembrandt: helping personalized medicine become a reality through integrative translational research. Mol Cancer Res (2009) 3.58
SOX2 silencing in glioblastoma tumor-initiating cells causes stop of proliferation and loss of tumorigenicity. Stem Cells (2009) 3.54
Mesenchymal differentiation mediated by NF-κB promotes radiation resistance in glioblastoma. Cancer Cell (2013) 2.98
Glioma stem cells: a midterm exam. Neuron (2008) 2.69
PLAGL2 regulates Wnt signaling to impede differentiation in neural stem cells and gliomas. Cancer Cell (2010) 2.68
Tumor suppressor PTEN: modulator of cell signaling, growth, migration and apoptosis. J Cell Sci (2001) 2.68
Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell (2012) 2.39
Most human non-GCIMP glioblastoma subtypes evolve from a common proneural-like precursor glioma. Cancer Cell (2014) 2.14
Wnt-1 signal induces phosphorylation and degradation of c-Myb protein via TAK1, HIPK2, and NLK. Genes Dev (2004) 1.87
EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell (2013) 1.44
Patient-specific orthotopic glioblastoma xenograft models recapitulate the histopathology and biology of human glioblastomas in situ. Cell Rep (2013) 1.44
Nemo-like kinase suppresses Notch signalling by interfering with formation of the Notch active transcriptional complex. Nat Cell Biol (2010) 1.41
Role of the TAK1-NLK-STAT3 pathway in TGF-beta-mediated mesoderm induction. Genes Dev (2004) 1.34
Frizzled 4 regulates stemness and invasiveness of migrating glioma cells established by serial intracranial transplantation. Cancer Res (2011) 1.30
Brain tumor stem cells: the cancer stem cell hypothesis writ large. Mol Oncol (2010) 1.30
Stem cell marker nestin and c-Jun NH2-terminal kinases in tumor and peritumor areas of glioblastoma multiforme: possible prognostic implications. Clin Cancer Res (2007) 1.25
Wnt activation is implicated in glioblastoma radioresistance. Lab Invest (2011) 1.22
Nemo-like kinase induces apoptosis in DLD-1 human colon cancer cells. Biochem Biophys Res Commun (2003) 1.16
MXI1, a putative tumor suppressor gene, suppresses growth of human glioblastoma cells. Cancer Res (1997) 1.15
Nemo-like kinase induces apoptosis and inhibits androgen receptor signaling in prostate cancer cells. Prostate (2009) 1.14
Wnt/β-catenin signaling is a key downstream mediator of MET signaling in glioblastoma stem cells. Neuro Oncol (2012) 1.09
Nemo-like kinase, a multifaceted cell signaling regulator. Cell Signal (2012) 1.07
Allelic losses of chromosome 10 in glioma tissues detected by quantitative single-strand conformation polymorphism analysis. Clin Chem (2006) 1.00
Nemo-like kinase (NLK) inhibits the progression of NSCLC via negatively modulating WNT signaling pathway. J Cell Biochem (2014) 0.89
Mxi1 inhibits the proliferation of U87 glioma cells through down-regulation of cyclin B1 gene expression. Br J Cancer (2002) 0.88
Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One (2013) 0.82
Wnt signaling induces GLT-1 expression in rat C6 glioma cells. J Neurochem (1999) 0.82
Beta-catenin expression in human neural cell lines following exposure to cytokines and growth factors. Neuropathology (2000) 0.82
Targeting the epithelial to mesenchymal transition in glioblastoma: the emerging role of MET signaling. Onco Targets Ther (2014) 0.96
WNT signaling in glioblastoma and therapeutic opportunities. Lab Invest (2015) 0.84
Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme. Oncotarget (2015) 0.78
Genomic and transcriptomic characterization of skull base chordoma. Oncotarget (2016) 0.77
CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget (2017) 0.75
CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget (2017) 0.75
Anti-SEMA3A Antibody: A Novel Therapeutic Agent to Suppress GBM Tumor Growth. Cancer Res Treat (2017) 0.75